M1 Kliniken AG investor news & press releases

| Investor News

  • Management is open to interested parties
  • Valuations in the peer group of up to 30 times the annual EBITDA
  • M1 Kliniken AG expects EBITDA of over EUR 27 million in 2024

| Investor News

By acquiring the German Nutri Care GmbH and its wholly-owned subsidiary, the Dutch online pharmacy "Direct Apotheke Venlo B.V.," M1 Kliniken AG (ISIN: DE000A0STSQ8) taps into a significant growth field and expands the value chain of its health services. Direct Apotheke Venlo B.V., based in Maasbree (NL), is one of the rapidly growing providers in the online pharmacy business for aesthetic pharmaceuticals, with current core markets in Germany and the Netherlands. In the fiscal year 2022, the company recorded double-digit million-euro revenues and continues on a growth trajectory.

| Investor News

  • Group sales increase by over 10% to EUR 236.6 million in the first nine months of the 2023 financial year (previous year: EUR 214.2 million).

  • Group EBITDA increases by over 55% from EUR 10.9 million to EUR 16.9 million.

  • The operating result (Group EBIT) increases by over 98% to EUR 12.9 million (previous year: EUR 6.5 million).

  • Beauty segment: sales increase of 28.5% to EUR 53.2 million (previous year: EUR 41.4 million) and sharp rise in the Beauty EBIT margin from 8.2% to 23.5%

| Investor News

  • 20th Location outside Germany opened in Bucharest, Romania
  • Break-even expected for foreign locations within the next 12 months
  • Subsidiary established in the USA: Market entry into the world's largest market for beauty medicine expected in 2024

| Investor News

  • Group revenue increases by around 9% to EUR 150.8 million in the first half of 2023 (previous year: EUR 138.7 million)
  • Group EBIT increases by over 60 % to EUR 7.3 million (previous year: EUR 4.5 million)
  • Beauty segment: sales increase of more than 33% to EUR 37.2 million and EBIT margin above 20 % for the first time

M1 Kliniken AG announces figures for the first quarter of 2023. Accordingly, the consolidated group revenue of the M1 Group increased by around 21% to EUR 76.8 million in the first quarter (previous year: EUR 63.5 million).

| Ad-hoc news

The Management Board of M1 Kliniken AG today resolved to repurchase up to 1,500,000 shares of the Company in a maximum total volume of EUR 10,800,000.00 (excluding incidental acquisition costs).

| Investor News

M1 Kliniken AG publishes preliminary figures for the financial year 2022. In the past financial year, the M1 Group was able to further expand its market position in the field of beauty medicine and opened eight new specialist medical centres in Germany and abroad.

| Investor News

The Supervisory Board of M1 Kliniken AG today appointed Mr. Attila Strauss to the Management Board of M1 Kliniken AG with immediate effect.

 

| Investor News

At its meeting today, the Supervisory Board of M1 Kliniken AG appointed Mr. Kilian Brenske (28, M.Sc.) to the management board of M1 Kliniken AG.

| Investor News

  • Group turnover decreases to EUR 214 million (EUR 236 million as of Q3-2021)
  • Group EBITDA amounts to EUR 10.9 million (previous year: EUR 12.0 million); EBIT amounts to EUR 6.5 million (previous year: EUR 7.8 million)
  • Beauty: Extension of regional expansion to Eastern Europe with opening of first beauty centre in Budapest/Hungary in September 2022

| Investor News

  • Group revenue falls to just under EUR 139 million (EUR 165 million in H1-2021)
  • Group EBITDA amounts to EUR 7.4 million (previous year: EUR 9.9 million); EBIT amounts to EUR 4.5 million (previous year: EUR 7.1 million)
  • Beauty: Increase in treatment and sales figures; five new centres already opened in 2022; no influence of the deteriorating consumer climate so far